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To examine single nucleotide polymorphism (SNP) associations with cerebral palsy in a 
multivariable analysis adjusting for potential clinical confounders and to assess SNP-SNP 
and SNP-maternal infection interactions as contributors to cerebral palsy. 
Methods 
A case-control study including 587 children with cerebral palsy and 1,154 control children 
without cerebral palsy. 39 candidate SNPs were genotyped in both mother and child.  Data 
linkage to perinatal notes and cerebral palsy registers was performed with a 
supplementary maternal pregnancy questionnaire.  History of known maternal infection 
during pregnancy was extracted from perinatal databases. 
Results 
Both maternal and fetal carriage of inducible nitrous oxide synthase (iNOS) SNP rs1137933 
were significantly negatively associated with cerebral palsy in infants born at less than 32 
weeks gestation after adjustment for potential clinical confounders and correction for 
multiple testing (OR 0.55, 95% CI 0.38-0.79; OR 0.57, 95% CI 0.4-0.82 respectively).  
Analysis did not show any statistically significant SNP-SNP or SNP-maternal infection 




Maternal and child iNOS SNPs are associated with reduced risk of cerebral palsy in infants 
born very preterm.  There was no evidence for statistically significant SNP-SNP or SNP-




Case-control, Cerebral Palsy, infection, interaction, pregnancy, SNP 
What is already known on this topic: 
• Single nucleotide polymorphism (SNP) associations with cerebral palsy have previously 
been reported.  Most reports do not adjust for clinical confounders and have not 
examined SNP-SNP or SNP-clinical interactions 
What this paper adds: 
•  SNPs in the iNOS gene are associated with cerebral palsy in infants born before 32 weeks 
gestation, after adjustment for clinical confounders. 
• Tests for interaction between SNPs and between SNPs and maternal infection during 




Cerebral palsy is defined as ‘‘a group of permanent disorders of the development of 
movement and posture, causing activity limitation that is attributed to non-progressive 
disturbances that occurred in the developing fetal or infant brain. The motor disorders of 
cerebral palsy are often accompanied by disturbances of sensation, perception, cognition, 
communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems’’ 
1
.  Cerebral palsy is a common paediatric condition affecting approximately 1.5 to more 
than 4 per 1,000 children born in the developed world, a prevalence that has changed 
little over the last 50 years despite large changes in obstetric care 
2-5
. Not only has the 
prevalence remained unchanged, but the majority of cases remain without a specific 
known cause. 
A number of clinical risk factors for cerebral palsy have been described in the literature 
including preterm birth 
6
, low birth weight centile 
7





 and a relative with cerebral palsy 
10
 but the currently known clinical risk 
factors do not explain the majority of cases. Because many of these risk factors may have 
a genetic component, researchers have investigated candidate SNPs as potential factors 
that increase genetic susceptibility for cerebral palsy.  Thrombophilic, inflammatory and 
apolipoprotein-E (APOE) SNPs have been the most extensively investigated with variable 
and weak associations reported (for systematic review see O’Callaghan et al. 
11
).  They 
include positive associations in individual studies and in a recent meta-analysis 
12
. The 
largest study investigating candidate SNP associations with cerebral palsy was recently 
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conducted by our group 
13
.  Univariable analyses of SNP associations 
14
 and 
epidemiological risk factors for cerebral palsy 
15
 have previously been published from this 
case-control study.  The initial analysis showed few significant SNP associations with the 
exception of prothrombin gene mutation and hemiplegia in infants delivered at term to 
mothers who reported having an infection during pregnancy.  This paper presents the 
multivariable analysis. 
Cerebral palsy is a complex disorder that is likely to be of multi-factorial origin and 
therefore SNP associations with cerebral palsy were examined after adjustment for 
potentially confounding clinical risk factors.  Interactions between maternal and fetal 
genotype that may modulate cerebral palsy risk were also tested; these interactions are 
potentially critical to understanding cerebral palsy given that many clinical risks described 
to date involve the maternal-fetal interface.  Finally, we sought significant interactions 
between genotype and reports of maternal infection during pregnancy that may modulate 








Materials and Methods 
Cohort 
This analysis utilises data collected as part of The Australian Cerebral Palsy Research Study 
cohort.  The original study design is described in detail elsewhere 
13
. In summary, mother-
child case and control pairs (one child per family) were recruited between July 2008 and 
March 2010 from around Australia with the following inclusion criteria: children were 
aged between 5 and 18 years, born in Australia and of Caucasian background. Five 
hundred and eighty-seven case families and 1,154 control families were recruited during 
the same time period and included in the analysis. Basic demographic details of the cohort 
are shown in Table 1. 
Cases 
Children with cerebral palsy were recruited from all states of Australia.  Invitations were 
sent to families by state cerebral palsy registers, cerebral palsy health service providers 
and special education schools.  Advertisement was also made using a website, flyers and 
media releases.  Comparison of case cohort demographics and clinical details (birth 
weight, gestational age, maternal age, cerebral palsy subtype and severity) was made with 
population wide Australian cerebral palsy data with good correlation (see supplementary 
material). 
Controls 
Children without cerebral palsy were recruited as the control cohort from all states of 
Australia.  Invitations were sent to families by schools and advertisement was also made 
using a website, flyers, media releases and recruitment booths in public places. 
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Comparison of control cohort demographics and clinical details (birth weight, gestational 
age and maternal age) was made with population wide Australian birth data with good 
correlation (see supplementary material). 
Clinical data 
Clinical data relating to both case and control cohorts were collected by linking to 
perinatal databases in each state of Australia.  Where data was not collected for national 
statistics (e.g. maternal smoking during pregnancy and maternal recreational drug use 
during pregnancy in some states) data were collected using a maternal questionnaire 
13
.  
For the case cohort, linkage was also made to cerebral palsy registers in each state of 
Australia and data on cerebral palsy subtype and severity was returned.  Data relating to 
reported maternal infection during pregnancy (e.g. proven genitourinary tract infection, 
pyrexia during labour, clinically recorded viral infection) were sourced from state held 
perinatal outcome data sets. While the maternal questionnaire collected further details 
about type of infection and timing, the data may be subject to maternal recall bias. Any 
infection when it had been recorded prospectively by health care professionals during 
pregnancy and at birth was used in preference to the maternal questionnaire.  There were 
too many infection types to meaningfully conduct infection subtype analysis. Placental 
pathology, bacteriology and virology results were not available. Cases were classed as 
hemiplegia, diplegia, quadriplegia or other, based on the diagnosis recorded in cerebral 
palsy registers.  Cases and controls were divided into the following gestational age 
subgroups: very preterm (≤32 weeks gestational age), late preterm (32-37 weeks 
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gestational age), and term (≥37 weeks gestational age). The number of participants and 
proportion in each subgroup group is shown in Table 1.   
Genetic Data 
 Candidate SNPs 
DNA samples were collected using buccal swabs.  The 39 functional candidate SNPs used 
are described in the published protocol of this study (Table 2) 
13
. The panel included 
candidate SNPs chosen for their association with 1) thrombophilia 2) inflammation and 3) 
other previously reported risk factors for cerebral palsy such as preterm birth.   
 Genotyping and Quality Control 
SNP genotyping was performed by the Australian Genome Research Facility (AGRF, 
Brisbane Node, Australia) on a MassARRAY iPLEX Gold System (Sequenom, San Diego, CA, 
USA).  Individuals were checked for Mendelian failures (<1% removed), sibling relationship 
(0.42% removed), gender inconsistencies between DNA analysis and participant 
questionnaires (0.62% removed) and samples with greater than 25% of SNP tests failing 
(0.5% removed as per McMichael et al. 
16
).  All SNPs achieved greater than 93% successful 
genotyping, two were excluded as they were non-polymorphic (rs17516265 – TGFB1, 
rs1715 – CR2-2) and one was excluded as it significantly differed from Hardy Weinberg 
equilibrium (rs1061170 – CFHY402H, p<0.05). Linkage disequilibrium testing showed that 
two SNPs had a correlation of >0.80% and could not be considered as independent tests 





Each fetal and maternal SNP was individually assessed by logistic regression for 
association with cerebral palsy.  To minimise the number of comparisons made, an 
additive genetic model for SNP data was used (each SNP coded as the number of minor 
alleles present). Logistic regression was then repeated for each SNP including adjustment 
for the following potential confounders: gestational age, multiple birth, maternal infection 
during pregnancy, maternal age, gender, maternal smoking and recreational drug use 
during pregnancy.  Until the precise sequence of events leading to cerebral palsy is 
clarified it remains difficult to select potential confounders.  Gestational age was included 
as a potential confounder (following similar analyses
17-19
) while Apgar score was not since 
it may be part of the cerebral palsy phenotype.   
Odds ratio (OR) and 95% confidence intervals (95% CI) are reported for all association 
tests conducted where p<0.05. To account for the large number of tests conducted 
(overall cerebral palsy association and each subgroup), SNP associations are corrected 




Cerebral palsy is a heterogeneous condition, with this diversity possibly reflecting 
different causal pathways for subtypes within the condition.  Associations with cerebral 
palsy subtypes hemiplegia, diplegia and quadriplegia, as well as gestational age subgroups 
very preterm (≤32 weeks gestational age), late preterm (32-37 weeks gestational age) or 
11 
 
term (≥37 weeks gestational age) are therefore described.  For all subtype analyses, the 
whole control cohort was used for comparison. 
Interactions 
Interactions between mother and child SNPs were assessed using logistic regression. 
While it is theoretically possible to test pair-wise interactions between all SNPs in the 
child’s panel, all SNPs in the mother’s panel, all clinical variables and then combinations 
thereof, this would create a large number of tests, most of which would be of little 
interest.  To limit multiple testing only a priori interaction tests were conducted.  Firstly, 
interactions between each individual maternal SNP and the same SNP in the child (this 
accounts for inherent genotypic correlation) are examined, and secondly; interactions 
between each individual SNP and maternal infection during pregnancy as reported in state 
held perinatal data sets (a possible clinical trigger) are also examined.  
Institutional Review Board 
Ethics approval was obtained from the research group’s institution (approval number REC 
1946/4/10) and from relevant committees in each state of Australia.  All cases and 






SNP Associations with Cerebral Palsy 
 
After adjustment for potential clinical confounders, two child SNPs (in genes encoding 
MMP-2 and TNF-α), and three maternal SNPs (in genes encoding IL-1β, TGF-β1 and TNF-α) 
remained significantly (p<0.05) associated with all types of cerebral palsy (see Table 3).  
These tests were no longer significant after FDR correction for multiple testing. 
SNP Associations with Cerebral Palsy Subtypes 
 
When considering all SNPs and analysing for cerebral palsy subtypes,  SNPs in genes 
encoding the following remained significantly (p<0.05) associated with hemiplegia – child 
MMP-2, maternal TNF-α and maternal Factor V Leiden; quadriplegia – child NPY and TNF-
α; very preterm birth – child iNOS, child PAI-2, maternal iNOS, maternal Factor V Leiden, 
maternal MBL+4; late preterm birth – child MMP-2, maternal TGF-β1 and term birth – 
child ADRB2, child TNF-α, child PAI-2, maternal NPY, maternal IL-1β, maternal TNF-α (see 
Table 4).  After conservative correction for multiple testing only maternal and child iNOS 
SNPs remained significantly associated with cerebral palsy in very preterm infants (OR 
0.55, 95% CI 0.38-0.79, p=0.05; OR 0.57, 0.4-0.82, p=0.05, respectively).  




All SNPs were assessed for interaction when the same SNP was carried by both mother 
and child.  A significant interaction was seen for SNP IL-10-819 (p=0.012); however this 
was not significant after correction for multiple testing (data not shown).  
Cerebral Palsy Associations and SNP-clinical infection interaction 
 
All SNPs were examined for interaction with maternal infection during pregnancy as 
reported in state held perinatal data sets.  There were no significant associations after 





This paper confirms in a multivariable analysis the association of only a few specific SNPs 
with cerebral palsy outcome and excludes other nominated candidate genes.  With the 
exception of maternal and child iNOS in children born at less than 32 weeks gestational 
age, SNPs did not remain significantly associated with cerebral palsy, cerebral palsy 
subtypes or gestational age subgroups after correction for multiple testing.   
iNOS SNPs have previously been associated with cerebral palsy in two small independent 
cohorts, however associations were not significant after correction for multiple testing.  
Gibson et al reported associations in a composite of all gestational age groups 
(heterozygous/homozygous versus normal, OR 1.29, 95% CI 1.00 –1.67; P=0.047) and in 
infants born at ≥37 weeks’ gestational age (heterozygous versus normal, OR 1.58, 95% CI 
1.12–2.23, P =0.009; heterozygous/ homozygous versus normal, OR 1.59, 95% CI 1.14 –
2.22; P=0.006)
21
.  Wu et al report an association of iNOS with cerebral palsy in infants born 
at ≥37 weeks’ gestational age (OR 1.9, 95% CI 1.2–3.1)
22
.   The observation of a negative 
association between iNOS and cerebral palsy in very preterm infants in this analysis is in 
contrast to previous studies and may reflect the larger cohort used combined with 
adjustment for clinical confounders and multiple testing. This inverse association is seen 
whether the SNP is present in the mother or the child.  iNOS SNP rs1137933 is a 
synonymous coding mutation and its effects are therefore likely to be mediated by linkage 
disequilibrium with other SNPs in the iNOS gene
23
.  It has previously been associated with 
Crohn’s disease
23
 and multiple sclerosis
24
 through inflammation mechanisms.  In the 
15 
 
context of cerebral palsy, either up regulation or down regulation of the immune response 
may leave the fetal brain susceptible to damage, caused either directly by the 
inflammatory response or resulting from neurotropic infectious agents.  It tempting to 
speculate that enhanced inflammatory capacity associated with this iNOS SNP conveys a 
protective effect for infection-associated cerebral palsy. Further studies, ideally in a 
prospective cohort with detailed phenotyping of the maternal and fetal inflammatory 
response and the various biologic pathogens will be required to support or refute this 
hypothesis.   
It is not possible in a retrospective study of cerebral palsy cases and controls to document 
the full range of maternal infections that may occur during pregnancy.  For this analysis, 
documentation of maternal infection during pregnancy was ascertained from state held 
perinatal data sets and may be under reported.  Prospective studies collecting such detail 
are currently impractical.  Thus, interaction of candidate SNPs and maternal infection 
during pregnancy could have been missed in this analysis. 
These results do not provide statistical evidence for SNP-SNP or SNP-infection interactions 
modulating the risk of cerebral palsy after correction for multiple testing.  This lack of 
evidence for association should not be interpreted as evidence for no association.  It is 
plausible that the application of FDR correction for multiple testing to a small group of 
candidate SNPs chosen because of prior knowledge is too conservative and significant 
associations have been missed.  Larger sample sizes are required to achieve adequate 
16 
 
power for these tests and will likely only be achievable using individual patient data meta-
analyses of data acquired from multiple studies.   
Other weaknesses of this study include the cohort sample size, although it is the largest 
reported to date.  The control cohort included only a small number of very preterm 
infants, which while typical of the general population, may mean that adjustment for this 
variable still leaves residual confounding.  Since gestational age is associated with cerebral 
palsy it would be ideal to match the cohorts for this variable; however the low incidence 
of very preterm delivery in the general population makes this impractical to achieve in a 
prospectively recruited case-control study. The results of this study remain to be 
replicated in an independent cohort.  Inclusion of reported maternal infection as a 
variable in regression models testing inflammatory SNP associations with cerebral palsy 
may result in over correction.  This would be the case if inflammatory SNPs only affected 
infection susceptibility. They may also modulate inflammation magnitude.  The study is 
also limited by the absence of cord blood samples which could be used to assess gene 
expression and protein data relevant to the SNPs examined.   The strengths of the current 
report include collection of both child and maternal DNA samples, the conservative use of 
correction for multiple testing and the parallel collection of well validated clinical data.  
Potential clinical applications of these findings could include development of predictive 
tools for cerebral palsy based on genetic profiling and clinical characteristics which might 
allow identification and monitoring of high risk groups.  Additional validation is required 




 Maternal and child iNOS SNPs are inversely associated with cerebral palsy in infants born 
very preterm.  Interaction between maternal and child SNPs and also SNP interactions 
with clinical infection were not significantly associated with cerebral palsy. 
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Table 1.   
Participant characteristics. 
Demographic Cases Controls 
Number of participants 587 1154 
 Males (%) 345 (58) 529(46) 
Range of birth years 1990-2009 1990-2009 
Average maternal age at birth of 
participating child (years) 
31.3 31.0 
Average gestational age (weeks) 35.3 39.3 
Number ≤32 weeks gestational age (%)† 164 (29.3) 9 (0.8) 
Number 32–37 weeks gestational age (%)† 87 (15.5) 65 (5.9) 
Number ≥ 37 weeks gestational age (%)† 309 (44.6) 1032 (93.3) 
Average birth weight (g) 2538 3456 
Hemiplegia 191 (33.4) N/A 
Diplegia 149 (26) N/A 
Quadriplegia 145 (25.3) N/A 




Table 2.   
SNPs examined. 
SNPs associated with an altered inflammatory 
response 
SNPs associated with thrombophilia Other SNPs, most associated with preterm birth 
Number SNP RS Number Number SNP RS Number Number SNP RS Number 
1 TNF-α 308 1800629 24 PAI-2_1 6098 33 APO-E_1 429358 
2 TNF-α+488 1800610 25 PAI-2_2 6103 34 APO-E_2 7412 
3 TNF-α-238 361525 26 THBD 1800576 35 iNOS (NOS2A) 1137933 
4 TLR4 299 4986790 27 FVL 6025 36 eNOS-922 1800779 
5 MBL codon 52 5030737 28 MTHFR 677 1801133 37 ADD1 4961 
6 MBL codon 54 1800450 29 MTHFR 1298 1801131 38 ADRB2 Q27E 1042714 
7 MBL codon 57 1800451 30 PGM 1799963 39 Y-specific Amelogenin
1
 
8 MBL-221 7096206 31 NPY C4112T 16135    
9 MBL+4 7095891 32 NPY A6411C 16476    
10 MBL-550 11003125       
11 IL-4-589 2243250       
12 IL-8 4073       
13 IL 1B+511 16944       
14 IL-10-819 1800871       
15 IL-6-174 1800795       
16 CR2-1 3813946       
17 CR2-2 1048971       
18 CR2-3 1715       
19 TGF-B1-29 1982073       
20 TGF-ß1-509 1800469       
21 CFH Y402H 1061170       
22 MMP-3 602128       







Maternal and child SNP associations with cerebral palsy. 
All tests use an additive genetic model. Adjustments made for gestational age, multiple births, maternal infection during pregnancy as reported in state 
held perinatal data sets, gender, maternal age, maternal smoking and recreational drug use during pregnancy. Only tests with adjusted p<0.05 after 
adjustment shown.   
 
  
Gene affected by SNP  Cases Controls Unadjusted Adjusted 
 Genotype n % n % OR (95%CI) P OR P 
FDR 
Corrected P 
Child MMP-2 C/C 308 53.7 689 60.3 
1.2 (1.02-1.42) 0.028 1.28 (1.04-1.56) 0.018 0.6  C/T 233 40.6 389 34.1 
 T/T 33 5.7 64 5.6 
Child TNF-α G/G 394 68.2 728 63.5 
0.85 (0.71-1.02) 0.09 0.79 (0.62-1.0) 0.047 0.7  G/A 166 28.7 381 33.2 
 A/A 18 3.1 37 3.2 
Maternal IL 1β  G/G 276 48.1 505 44.9 
0.89 (0.76-1.04) 0.14 0.79 (0.66-0.96) 0.017 0.6  A/G 244 42.5 493 43.8 
 A/A 54 9.4 127 11.3 
Maternal TGF-β G/G 275 47.8 626 55.7 
1.24 (1.06-1.44) 0.007 1.24 (1.03-1.50) 0.025 0.6  G/A 246 42.8 405 36 
 A/A 54 9.4 93 8.3 
Maternal TNF-α  G/G 387 66.6 724 63.4 
0.86 (0.72-1.03) 0.11 0.80 (0.63-1.0) 0.049 0.7  G/A 178 30.6 371 32.5 




Maternal and child SNP associations with cerebral palsy subtypes. 
Gene affected by SNP  Cases Controls Unadjusted Adjusted 





Child MMP-2 C/C 95 50.5 689 60.3 
1.35 (1.06-1.72) 0.016 1.42 (1.07-1.88) 0.015 0.6  C/T 79 42.0 389 34.1 
 T/T 14 7.4 64 5.6 
Maternal TNF-α G/G 130 68.8 724 63.4 
0.8 (0.6-1.06) 0.12 0.66 (0.47-0.94) 0.016 0.6  G/A 54 28.6 371 32.5 
 A/A 5 2.6 47 4.1 
Maternal Factor V Leiden G/G 173 90.6 1099 95.5 
2.01 (1.1-3.45) 0.019 1.98 (1.07-3.65) 0.038 0.9  G/A 18 9.4 50 4.3 
 A/A 0 0.0 2 0.2 
Quadriplegia 
Child NPY T/T 25 17.9 298 26.2 
1.32 (1.02-1.69) 0.031 1.41 (1.02-1.95) 0.036 0.8  G/T 74 52.9 565 49.7 
 G/G 41 19.3 273 24.0 
Child TNF-α 308 G/G 105 74.5 728 63.5 
0.62 (0.43-0.89) 0.007 0.54 (0.33-0.87) 0.008 0.5  G/A 34 24.1 381 33.2 
 A/A 2 1.4 37 3.2 
Very preterm birth (cases born at gestational age ≤32 weeks)  
Child iNOS C/C 114 69.1 659 57.7 
0.68 (0.50-0.92) 0.009 0.57 (0.4-0.82) 0.001 0.05  C/T 44 26.7 420 36.8 
 T/T 7 4.2 63 5.5 
Child PAI-2 A/A 100 67.6 632 59.2 
0.72 (0.53-0.99) 0.04 0.67 (0.46-0.96) 0.026 0.4  G/A 43 29.1 373 35.0 
 G/G 5 3.4 62 5.8 
Maternal iNOS C/C 114 69.1 645 56.3 
0.6 (0.44-0.82) 0.0009 0.55 (0.38-0.79) 0.0007 0.05  C/T 47 28.5 438 38.2 
 T/T 4 2.4 63 5.5 
Maternal Factor V Leiden G/G 149 89.8 1099 95.5 
2.19 (1.26-3.8) 0.010 2.37 (1.28-4.41) 0.01 0.3  G/A 17 10.2 50 4.3 
 A/A 0 0 2 0.2 
Maternal MBL+4 G/G 114 70.4 672 59.4 
0.66 (0.48-0.9) 0.007 0.7 (0.49-1.0) 0.04 0.5  G/A 43 26.5 404 35.7 
 A/A 5 3.1 56 4.9 
Late Preterm birth (cases born at gestational age 32-37 weeks) 
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Gene affected by SNP  Cases Controls Unadjusted Adjusted 




Child MMP-2 C/C 44 52.4 689 60.3 
1.47 (1.05-2.05) 0.03 1.57 (1.1-2.25) 0.016 0.7  C/T 29 34.5 389 34.1 
 T/T 11 13.1 64 5.6 
Child TGF- β1 G/G 32 38.1 626 55.7 
1.49 (1.08-2.05) 0.02 1.53 (1.08-2.16) 0.02 0.7  G/A 45 53.6 405 36 
 A/A 7 8.3 93 8.3 
Term (cases born at ≥37 weeks gestational age) 
Child ADRB2 C/C 99 33.3 354 31.0 
0.87 (0.72-1.05) 0.14 0.81 (0.66-1) 0.04 0.6  G/C 155 52.2 576 50.4 
 G/G 43 14.5 213 18.6 
Child TNF-α  G/G 213 69.6 728 63.5 
0.78 (0.61-1) 0.04 0.76 (0.59-0.99) 0.04 0.6  G/A 86 28.1 381 33.2 
 A/A 7 2.3 37 3.2 
Child PAI-2 C/C 199 66.1 666 58.8 
0.77 (0.61-0.96) 0.018 0.79 (0.62-1) 0.05 0.6  C/G 90 29.9 403 35.6 
 G/G 12 4.0 64 5.6 
Maternal NPY  T/T 94 31.0 304 26.7 
0.84 (0.7-1) 0.05 0.81 (0.67-0.99) 0.04 0.6  G/T 151 49.8 564 49.6 
 G/G 58 19.1 269 23.7 
Maternal IL-β1  G/G 149 49.0 505 44.9 
0.87 (0.72-1.05) 0.15 0.79 (0.64-0.97) 0.02 0.6  A/G 127 41.8 493 43.8 
 A/A 28 9.2 127 11.3 
Maternal TNF-α  G/G 209 68.5 724 63.4 
0.78 (0.62-0.99) 0.04 0.76 (0.62-1) 0.05 0.6  G/A 90 29.5 371 32.5 
 A/A 6 2.0 47 4.1 
All tests use an additive genetic model. Adjustments made for multiple birth, maternal infection during pregnancy as reported in state held perinatal data 
sets, gender, maternal age, maternal smoking and recreational drug use during pregnancy. Gestational age was adjusted for in tests examining hemiplegia, 
diplegia and quadriplegia. Only tests with adjusted p<0.05 after adjustment shown. 
 
 
 
